Literature DB >> 24287071

Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Catherine Diefenbach1, Ranjana Advani.   

Abstract

Although most patients with Hodgkin lymphoma (HL) are cured with primary therapy, patients with primary refractory disease or relapse after initial treatment have poor outcomes and represent an unmet medical need. Recent advances in unraveling the biology of HL have yielded a plethora of novel targeted therapies. This review provides an overview of the data behind the hype generated by these advances and addresses the question of whether or not clinically these targeted therapies offer hope for patients with HL.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brentuximab vedotin; Hodgkin lymphoma; Relapsed disease; Targeted therapies

Mesh：

Substances：

Year:  2014        PMID： 24287071      PMCID： PMC4023679          DOI： 10.1016/j.hoc.2013.10.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  80 in total

1.  High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.

Authors:  A van den Berg; L Visser; S Poppema
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.

Authors:  Mark H Kirschbaum; Bryan H Goldman; Jasmine M Zain; James R Cook; Lisa M Rimsza; Stephen J Forman; Richard I Fisher
Journal:  Leuk Lymphoma       Date:  2011-09-19

3.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

4.  Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.

Authors:  Conrad R Cruz; Ulrike Gerdemann; Ann M Leen; Jessica A Shafer; Stephanie Ku; Benjamin Tzou; Terzah M Horton; Andrea Sheehan; Amanda Copeland; Anas Younes; Cliona M Rooney; Helen E Heslop; Catherine M Bollard
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

5.  Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

Authors:  Anas Younes; Anna Sureda; Dina Ben-Yehuda; Pier Luigi Zinzani; Tee-Chuan Ong; H Miles Prince; Simon J Harrison; Mark Kirschbaum; Patrick Johnston; Jennifer Gallagher; Christophe Le Corre; Angela Shen; Andreas Engert
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

6.  Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma.

Authors:  Lara Cattaruzza; Annunziata Gloghini; Karin Olivo; Raffaele Di Francia; Debora Lorenzon; Rosaria De Filippi; Antonino Carbone; Alfonso Colombatti; Antonio Pinto; Donatella Aldinucci
Journal:  Int J Cancer       Date:  2009-09-01       Impact factor: 7.396

7.  Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines.

Authors:  Daniela Buglio; Georgios V Georgakis; Shino Hanabuchi; Kazuhiko Arima; Noor M Khaskhely; Yong-Jun Liu; Anas Younes
Journal:  Blood       Date:  2008-06-09       Impact factor: 22.113

8.  Epigenetic modifiers: basic understanding and clinical development.

Authors:  Richard L Piekarz; Susan E Bates
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

9.  Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

Authors:  Kristie A Blum; Jeffrey L Johnson; Donna Niedzwiecki; George P Canellos; Bruce D Cheson; Nancy L Bartlett
Journal:  Leuk Lymphoma       Date:  2007-07

Review 10.  Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.

Authors:  Thomas E Witzig; Scott H Kaufmann
Journal:  Curr Treat Options Oncol       Date:  2006-07
View more
  4 in total

1.  Simultaneous occurrence of Hodgkin's lymphoma and multiple myeloma: A case report and review of the literature.

Authors:  Chen Huang; Guimin Zhao; Lianjing Wang; Huichao Zhang; Xiaolin Wu; Mingzeng Zhang; Ruijuan Ma; Ling Wang; Yueping Liu; Lihong Liu
Journal:  Oncol Lett       Date:  2016-04-27       Impact factor: 2.967

2.  The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.

Authors:  Giorgio La Nasa; Marianna Greco; Roberto Littera; Sara Oppi; Ivana Celeghini; Rossella Caria; Sara Lai; Rita Porcella; Massimo Martino; Alessandra Romano; Francesco Di Raimondo; Andrea Gallamini; Carlo Carcassi; Giovanni Caocci
Journal:  J Hematol Oncol       Date:  2016-03-16       Impact factor: 17.388

3.  HLA-G expression and role in advanced-stage classical Hodgkin lymphoma.

Authors:  G Caocci; M Greco; D Fanni; G Senes; R Littera; S Lai; P Risso; C Carcassi; G Faa; G La Nasa
Journal:  Eur J Histochem       Date:  2016-04-11       Impact factor: 3.188

Review 4.  Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.

Authors:  Poonam Nagpal; Mohamed R Akl; Nehad M Ayoub; Tatsunari Tomiyama; Tasheka Cousins; Betty Tai; Nicole Carroll; Themba Nyrenda; Pritish Bhattacharyya; Michael B Harris; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  Oncotarget       Date:  2016-10-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.